Company news

Tiziana Life Sciences Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

August 22, 2023

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

August 14, 2023

Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer

June 12, 2023

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

June 4, 2023

Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform

May 22, 2023

Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

May 16, 2023

Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

April 26, 2023

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

April 25, 2023

Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

April 23, 2023

Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

April 19, 2023

Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

April 17, 2023

Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment

April 16, 2023

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

April 12, 2023

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

April 9, 2023

Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

April 3, 2023

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in...

March 30, 2023

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

March 27, 2023

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

March 16, 2023

Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

March 7, 2023

Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

January 3, 2023

Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

January 2, 2023

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

December 26, 2022

Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study

December 14, 2022

Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements

December 13, 2022

Tiziana Life Sciences Announces Date of Annual General Meeting 2022

December 5, 2022

Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects

November 22, 2022

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

November 9, 2022

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

November 2, 2022

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

November 1, 2022

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

October 25, 2022

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

October 11, 2022

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

September 28, 2022

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

September 27, 2022

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

September 19, 2022

Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis

September 14, 2022

Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease

July 31, 2022

Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

July 17, 2022

Tiziana Life Sciences Announces Resignation of CEO

July 14, 2022

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

June 7, 2022

Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance

May 23, 2022

FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab

April 4, 2022

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

March 24, 2022

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

March 9, 2022

Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease

February 3, 2022

Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million

January 23, 2022

Tiziana Life Sciences Announces Death of Director

January 12, 2022

Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

January 9, 2022

Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ

October 20, 2021

Tiziana Life Sciences - Scheme Effective Date

October 19, 2021

Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting

September 26, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 13 decks. Every deck is listed under its year.